Warren Nighan, Jr. Sells 4,060 Shares of AngioDynamics, Inc. (NASDAQ:ANGO) Stock

AngioDynamics, Inc. (NASDAQ:ANGO) SVP Warren Nighan, Jr. sold 4,060 shares of the business’s stock in a transaction dated Thursday, January 16th. The stock was sold at an average price of $12.31, for a total transaction of $49,978.60. Following the sale, the senior vice president now directly owns 41,817 shares in the company, valued at $514,767.27. The trade was a 8.85 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

AngioDynamics Trading Down 2.7 %

Shares of ANGO stock opened at $12.43 on Friday. AngioDynamics, Inc. has a 12 month low of $5.26 and a 12 month high of $13.13. The stock has a market cap of $503.04 million, a P/E ratio of -2.21 and a beta of 0.59. The company has a 50 day simple moving average of $8.75 and a two-hundred day simple moving average of $7.66.

AngioDynamics (NASDAQ:ANGO) last announced its earnings results on Wednesday, January 8th. The medical instruments supplier reported ($0.04) EPS for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.07. AngioDynamics had a negative net margin of 79.38% and a negative return on equity of 7.26%. The business had revenue of $72.90 million during the quarter, compared to analysts’ expectations of $70.93 million. During the same period in the prior year, the company earned ($0.05) earnings per share. The firm’s revenue was down .1% on a year-over-year basis. As a group, equities analysts forecast that AngioDynamics, Inc. will post -0.36 earnings per share for the current year.

Analyst Upgrades and Downgrades

ANGO has been the topic of several analyst reports. HC Wainwright upped their target price on shares of AngioDynamics from $14.00 to $15.00 and gave the stock a “buy” rating in a research note on Friday, January 10th. Canaccord Genuity Group dropped their target price on shares of AngioDynamics from $13.00 to $12.00 and set a “buy” rating on the stock in a research note on Friday, October 4th.

Institutional Trading of AngioDynamics

Hedge funds and other institutional investors have recently modified their holdings of the company. Quarry LP increased its stake in shares of AngioDynamics by 75.1% in the second quarter. Quarry LP now owns 6,047 shares of the medical instruments supplier’s stock worth $37,000 after purchasing an additional 2,594 shares in the last quarter. CWM LLC increased its stake in shares of AngioDynamics by 981.3% in the third quarter. CWM LLC now owns 9,732 shares of the medical instruments supplier’s stock worth $76,000 after purchasing an additional 8,832 shares in the last quarter. Mackenzie Financial Corp purchased a new stake in shares of AngioDynamics in the second quarter worth $80,000. Wealth Enhancement Advisory Services LLC purchased a new stake in shares of AngioDynamics in the third quarter worth $86,000. Finally, AE Wealth Management LLC purchased a new stake in shares of AngioDynamics in the second quarter worth $87,000. 89.43% of the stock is owned by hedge funds and other institutional investors.

About AngioDynamics

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.